UNI-MB - logo
UMNIK - logo
 
E-resources
Full text
Peer reviewed
  • Molecularly targeted cancer...
    Huang, Min; Shen, Aijun; Ding, Jian; Geng, Meiyu

    Trends in pharmacological sciences (Regular ed.), 01/2014, Volume: 35, Issue: 1
    Journal Article

    Highlights • Tumor heterogeneity is the key factor underlying limited response rate to targeted therapy. • Personalized medicines depend on biomarkers for selecting patients and directing therapy. • Co-development of predictive and response biomarkers is required for drug development. • PDX model-based trials mimicking human patients may improve biomarker discovery.